<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10952773</article-id><article-id pub-id-type="pmc">2363532</article-id><article-id pub-id-type="pii">6691314</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1314</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nocera</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Baudin</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pellegriti</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cailleux</surname><given-names>A F</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mechelany-Corone</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Schlumberger</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><collab>the Groupe d'Etude des Tumeurs a Calcitonine (GETC)</collab></contrib></contrib-group><aff id="aff1"><label>1</label>Service de M&#x000e9;decine Nucl&#x000e9;aire et de Canc&#x000e9;rologie Endocrinienne, Institute Gustave-Roussy, Villejuif Cedex, 94805, France</aff><aff id="aff2"><label>2</label>Service de M&#x000e9;decine Nucl&#x000e9;aire, Centre Ren&#x000e9; Huguenin, Saint-Cloud, 92210, France</aff><pub-date pub-type="epub"><day>17</day><month>08</month><year>2000</year></pub-date><pub-date pub-type="ppub"><month>09</month><year>2000</year></pub-date><volume>83</volume><issue>6</issue><fpage>715</fpage><lpage>718</lpage><history><date date-type="received"><day>18</day><month>01</month><year>2000</year></date><date date-type="rev-recd"><day>26</day><month>04</month><year>2000</year></date><date date-type="accepted"><day>01</day><month>05</month><year>2000</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Combinations of doxorubicin and streptozocin and 5-FU and dacarbazine were given alternately to 20 patients with metastatic medullary thyroid carcinoma. Three partial responses and 10 long-term stabilizations were observed. No unexpected toxicity occurred. &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>chemotherapy</kwd><kwd>medullary thyroid carcinoma</kwd></kwd-group></article-meta></front></article>


